EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

PrEP4Her: Evaluating the Reach, Adoption, Preliminary Effectiveness and Fidelity of a Multi‐Component Hybrid Type 3 Trial Designed to Increase PrEP Prescriptions for Black Women Receiving Gynaecologic Care in a University‐Affiliated Women's Health Setting in the United States South

Anais Mahone iD, Audra Williams iD, Dave Cleveland, Bernadette Johnson, Grace Watson, Mirjam-Colette Kempf, Lynn T Matthews iD, Michael J Mugavero iD, Latesha E Elopre

Journal of the International AIDS Society · 2026-10 · 29 (S5)

DOI: 10.1002/jia2.70208 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of the International AIDS Society, online erschienen am 08.10.2026. Verfasst von Anais Mahone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Black or African American, Drug Prescriptions, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To address suboptimal HIV pre‐exposure prophylaxis (PrEP) uptake among Black women, we designed PrEP4Her, a multi‐phase, multi‐component implementation strategy aimed to increase PrEP prescriptions among women receiving routine health services at a university‐affiliated gynaecology (GYN) clinic located in the Southeastern United States.

Methods

Informed by intervention mapping, PrEP4Her, a hybrid type 3 trial, was piloted over 8 months, January 2024–August 2024, and the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE‐AIM) conceptual framework guided the evaluation of proximal implementation outcomes. In this manuscript, we present (1) Reach (the number of Black women prescribed PrEP and the proportion of PrEP prescribed to women with an indication, having a sexually transmitted infection (STI) within 12 months and/or reporting >1 sex partners collected from a universal health screener); (2) Adoption (the number of PrEP prescribers); (3) Preliminary Effectiveness (PrEP prescribed over time). Also, we measured the number of Black women who self‐reported talking to a doctor about PrEP as a secondary outcome (Fidelity) . We collected evaluative data from the electronic health record (EHR), sexual health screener and self‐administered post‐visit survey. Descriptive statistics were utilized to describe the sample, and chi‐square tests examined the relationships between patient characteristics and talking to providers about PrEP. Analyses were completed in October 2025.

Results

EHR data indicate there were 1274 unique first clinic visits. Most women identified as Black race (58%) and, on average, were 34 (±11.3) years old. Ten PrEP prescriptions were written by seven prescribers (i.e. adoption). Among women prescribed PrEP, nine identified as Black women and none had a recent STI (i.e. reach). PrEP was prescribed once before the pilot, eight times during the pilot and once in the month after the pilot. However, PrEP was not prescribed to women with PrEP indications ( N = 85) (i.e. preliminary effectiveness). Nearly half (43%) of surveyed women reported talking to a provider about PrEP (i.e. fidelity); most (49%) identified as Black race. Chi‐square tests show significant differences by race ( p = 0.02).

Conclusions

We observed an increase in PrEP prescriptions from before to during the pilot period; however, 85 women with PrEP indications were not prescribed PrEP. Future research will further evaluate PrEP4Her's acceptability and feasibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsBlack or African AmericanDrug PrescriptionsHIV InfectionsPre-Exposure ProphylaxisAdultFemaleHumansMiddle AgedYoung AdultAdherence InterventionsSoutheastern United StatesUniversitiesWomen's Health

Stichwörter der Autor:innen

HIV preventionimplementation sciencepre‐exposure prophylaxis (PrEP)sexual healthwomen's health

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Division of Women's Reproductive Healthcare, Department of Obstetrics and Gynecology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • University of Alabama at Birmingham (UAB) Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Schools of Nursing, Public Health and Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • School of Medicine, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Anais Mahone, Audra Williams, Lynn T Matthews, Michael J Mugavero

Förderung

  • NIMH NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Mahone, A., Williams, A., Cleveland, D., Johnson, B., Watson, G., Kempf, M. C., Matthews, L. T., Mugavero, M. J., & Elopre, L. E. (2026). PrEP4Her: Evaluating the Reach, Adoption, Preliminary Effectiveness and Fidelity of a Multi‐Component Hybrid Type 3 Trial Designed to Increase PrEP Prescriptions for Black Women Receiving Gynaecologic Care in a University‐Affiliated Women's Health Setting in the United States South. Journal of the International AIDS Society, 29(S5). https://doi.org/10.1002/jia2.70208

Vancouver

Mahone A, Williams A, Cleveland D, Johnson B, Watson G, Kempf MC, et al. PrEP4Her: Evaluating the Reach, Adoption, Preliminary Effectiveness and Fidelity of a Multi‐Component Hybrid Type 3 Trial Designed to Increase PrEP Prescriptions for Black Women Receiving Gynaecologic Care in a University‐Affiliated Women's Health Setting in the United States South. Journal of the International AIDS Society. 2026;29(S5). doi:10.1002/jia2.70208

BibTeX
@article{Mahone2026,
  author = {Mahone, Anais and Williams, Audra and Cleveland, Dave and Johnson, Bernadette and Watson, Grace and Kempf, Mirjam-Colette and Matthews, Lynn T and Mugavero, Michael J and Elopre, Latesha E},
  title = {PrEP4Her: Evaluating the Reach, Adoption, Preliminary Effectiveness and Fidelity of a Multi‐Component Hybrid Type 3 Trial Designed to Increase PrEP Prescriptions for Black Women Receiving Gynaecologic Care in a University‐Affiliated Women's Health Setting in the United States South},
  journal = {Journal of the International AIDS Society},
  year = {2026},
  volume = {29},
  number = {S5},
  doi = {10.1002/jia2.70208}
}
Kostenlos starten →